COLLEGIUM PHARMACEUTICAL, INC COLL
Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder ("ADHD") and moderate to severe pain. We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the "Nucynta Products"), and Symproic, in the United States.
On September 3, 2024, we acquired Ironshore, which had developed and obtained commercial approval to market Jornay PM in the United States.
Jornay PM is a central nervous system ("CNS") stimulant prescription medicine that contains methylphenidate HCl, a Schedule II methylphenidate, which was approved by the U.S. Food and Drug Administration ("FDA") in August 2018 for the treatment of ADHD in people six years of age and older and currently the only FDA-approved stimulant medication that is dosed in the evening.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M | $310.0M | $296.7M | $280.4M | $28.5M | $1.7M |
| Cost of revenue | $317.3M | $254.1M | $240.6M | $254.4M | $126.3M | $130.2M | $193.7M | $165.7M | $2.6M | $213.0K |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M | $179.8M | $103.0M | $114.7M | $25.9M | $1.5M |
| R&D | — | $0 | $0 | $4.0M | $9.5M | $9.8M | $10.3M | $8.7M | $8.6M | $14.9M |
| SG&A | $284.8M | $210.4M | $159.2M | $172.2M | $119.0M | $113.8M | $116.4M | $126.8M | $92.8M | $80.6M |
| Total operating expenses | $283.6M | $207.4M | $159.2M | $176.2M | $133.0M | $123.6M | $126.8M | $135.4M | $103.9M | $95.8M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M | $56.2M | -$23.7M | -$20.7M | -$75.4M | -$94.1M |
| Interest expense | $82.3M | $74.0M | $83.3M | $63.2M | $21.0M | $28.9M | $909.0K | $20.1M | — | $94.0K |
| Pre-tax income | $92.6M | $98.6M | $75.7M | -$28.8M | -$3.4M | $27.6M | -$22.7M | -$39.1M | — | — |
| Income tax | $29.7M | $29.4M | $27.6M | $3.8M | $74.9M | $830.0K | $0 | — | — | — |
| Net income | $63.0M | $69.0M | $48.0M | -$25.0M | $72.0M | $26.8M | -$22.7M | -$39.1M | -$74.9M | -$94.2M |
| EPS, basic | 1.98 | 2.14 | 1.43 | -0.74 | 2.05 | 0.78 | -0.68 | -1.19 | — | -3.88 |
| EPS, diluted | 1.73 | 1.86 | 1.29 | -0.74 | 1.86 | 0.76 | -0.68 | -1.19 | -2.47 | -3.88 |
| Shares, diluted (wtd. avg.) | 39.7M | 40.4M | 41.8M | 33.8M | 41.0M | 35.2M | 33.5M | 33.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $231.3M | $70.6M | $238.9M | $176.2M | $189.0M | $176.7M | $170.0M | $146.6M | $118.8M | $153.3M |
| Short-term investments | $155.4M | $94.2M | $76.3M | — | — | — | — | — | — | — |
| Receivables | $211.3M | $228.5M | $179.5M | $183.1M | $105.8M | $83.3M | $73.0M | $77.9M | $10.0M | $2.1M |
| Inventory | $40.9M | $35.6M | $32.3M | $46.5M | $17.4M | $15.6M | $9.6M | $7.8M | $1.8M | $1.3M |
| Total current assets | $691.4M | $482.3M | $537.6M | $420.0M | $315.5M | $277.9M | $255.7M | $237.5M | $133.5M | $158.6M |
| Property, plant and equipment | $12.0M | $14.3M | $16.0M | $19.5M | $19.5M | $19.0M | $11.9M | $9.3M | $1.8M | $1.0M |
| Goodwill | $145.9M | $162.3M | $133.9M | $133.7M | — | — | — | — | — | — |
| Other intangibles | $669.5M | $891.4M | $421.7M | $567.5M | $268.7M | $335.9M | $29.5M | $44.3M | — | — |
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.1M | $643.8M | $306.3M | $291.2M | $135.6M | $162.0M |
| Accounts payable | $10.7M | $3.9M | $8.7M | $3.5M | $4.2M | $10.0M | $6.2M | $12.2M | $5.7M | $9.1M |
| Total current liabilities | $440.0M | $509.5M | $457.9M | $433.7M | $279.6M | $239.5M | $201.8M | $189.1M | $31.5M | $25.6M |
| Long-term debt | — | — | — | — | — | — | $11.5M | $11.5M | — | $4.1M |
| Total liabilities | $1.36B | $1.43B | $947.9M | $979.3M | $489.1M | $457.8M | $218.9M | $199.7M | $31.5M | $27.1M |
| Retained earnings | -$101.1M | -$164.0M | -$233.2M | -$281.3M | -$256.3M | -$333.1M | -$359.9M | -$337.2M | -$298.0M | -$223.2M |
| Total equity | $301.7M | $228.8M | $195.4M | $194.8M | $202.9M | $186.0M | $87.4M | $91.6M | $104.1M | $134.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $329.3M | $205.0M | $274.7M | $124.2M | $103.6M | $93.9M | $27.8M | $169.4M | -$67.0M | -$75.1M |
| Depreciation and amortisation | $4.2M | $3.9M | $3.5M | $2.7M | $1.7M | $870.0K | $731.0K | $1.1M | $594.0K | $655.0K |
| Stock-based compensation | $41.9M | $32.4M | $27.1M | $22.9M | $24.3M | $21.9M | $16.5M | $13.8M | $7.9M | $5.8M |
| Capital expenditure | $1.7M | $1.7M | $461.0K | $1.6M | $1.9M | $5.5M | $6.4M | $5.5M | $990.0K | $477.0K |
| Investing cash flow | -$63.5M | -$287.8M | -$70.8M | -$573.7M | -$1.9M | -$373.8M | -$6.4M | -$24.4M | -$990.0K | -$3.0M |
| Financing cash flow | -$110.2M | -$60.6M | -$140.2M | $436.7M | -$89.3M | $286.5M | $2.0M | -$117.2M | $33.5M | $135.6M |
| Buybacks | $25.1M | $60.0M | $75.0M | $14.1M | $47.9M | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-024063.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $28.5M | $280.4M | $296.7M | $310.0M | $276.9M | $463.9M | $566.8M | $631.4M | $780.6M |
| Gross profit | $1.5M | $25.9M | $114.7M | $103.0M | $179.8M | $150.6M | $209.5M | $326.2M | $377.3M | $463.3M |
| Net income | -$94.2M | -$74.9M | -$39.1M | -$22.7M | $26.8M | $72.0M | -$25.0M | $48.0M | $69.0M | $63.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |